🧬 Endocrinology Update: AI Predicts Insulin Resistance, Ozempic Kidney Approval, Teplizumab Launch and More
From AI breakthroughs and next-gen diabetes therapies to regulatory shifts and biotech trials, this week’s update highlights the most impactful developments transforming how we understand, prevent, and treat endocrine disorders. Whether you’re a clinician, researcher, or health tech enthusiast—this is your weekly dose of what’s next.
📌 In This Episode:
💊 UNC launches a Phase 3 trial for cadisegliatin in adults with Type 1 diabetes, aiming to improve glycemia without increasing hypoglycemia risk
⚠️ FDA announces enforcement action against unapproved animal-derived thyroid medications, urging transition to approved alternatives
🇬🇧 UK approves teplizumab, the first immunotherapy to delay the onset of Type 1 diabetes by up to three years
🧠 AI predicts insulin resistance using just fasting glucose and simple body metrics, achieving greater than 97 percent accuracy
🇨🇦 Canada approves Ozempic to slow progression of kidney disease in people with Type 2 diabetes, reducing risk of failure by 24 percent
🤖 UVA researchers call for a fully automated artificial pancreas using AI and dual-hormone delivery for complete closed-loop insulin control
🤰 Prenatal metformin use in PCOS reduces viral infections during pregnancy but may increase allergy and eczema risk in offspring
🧪 Sanofi begins Phase 2a trial of SAR442970, a dual-action nanobody targeting beta-cell preservation in newly diagnosed Type 1 diabetes
🧍♂️ Wearables show potential to prevent diabetes in childhood cancer survivors by enabling personalized, continuous glucose monitoring
🧬 Elevated TgAb antibody levels above 440 IU/mL are found to strongly predict thyroid cancer recurrence, altering long-term follow-up strategies
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, thyroid, and metabolic health
#Endocrinology #Diabetes #ThyroidHealth #AIinHealthcare #Ozempic #Teplizumab #Metformin #Sanofi #ArtificialPancreas #MedicalNews #LucidQuest #KidneyHealth #PCOS #InsulinResistance
“